

CD27 expression on allergen-specific T cells: A new surrogate for successful allergen-specific immunotherapy?

Stefanie Gilles, PhD,^a and Claudia Traidl-Hoffmann, MD^{a,b} Munich, Germany

Key words: Allergen-specific immunotherapy, T cells, differentiation, peptide–MHC class II tetramers, costimulation

To date, allergen-specific immunotherapy (ASIT) is the only causal treatment for allergic diseases. The principle of ASIT is to administer gradually increasing doses of allergen, either as allergen extracts or as recombinant allergen. The aim is to reprogram the allergen-specific immune response from a T_H2-driven IgE-dominated response toward a tolerant state. By inducing immune tolerance to an allergen, diseases such as allergic rhinitis might even be prevented in progressing toward a severe chronic disorder, such as asthma. Although the concept of specific immunotherapy is more than 100 years old,¹ our knowledge about the underlying immunologic mechanisms is limited (for overview, see Fig 1^{2,3}). Moreover, some patients are clinically unresponsive to ASIT, and the identification of solid predictors for successful ASIT remains an unmet clinical need.

In this issue of the *Journal*, Wambre et al² demonstrate that ASIT leads to selective elimination of terminally differentiated allergen-specific T_H2 cells in the peripheral blood of patients with alder pollen allergy. Allergen-specific effector cells were characterized by lack of expression of CD27, the TNF receptor superfamily member of costimulatory molecules. This important study implies that the differentiation state determines the pathogenic relevance of allergen-specific T cells and that elimination of terminally differentiated allergen-specific T_H2 cells might be a prerequisite for the induction of specific tolerance. Importantly, the results of this study could lead to the development of predictive markers for the clinical success of ASIT.

The first transient effect of ASIT is an early increase in allergen-specific IgE levels but also in specific IgG₁ and IgG₄ antibody levels. The biologic relevance of increases in immunoreactive serum IgG and IgG₄ levels after ASIT has been questioned because of the poor correlation with improvement in clinical symptoms. As levels of specific IgG, especially IgG₄, continue to increase, specific IgE levels gradually decrease in the course

of ASIT, accompanied by blunting of seasonal increases in IgE.³ This can most likely be explained by the differentiation of increasing numbers of regulatory T cells, shifting the cytokine profile from a T_H2 toward a regulatory cytokine pattern.^{4,5} In addition to regulatory T cells, allergen-specific T_H1 cells seem to contribute to the counterbalancing of T_H2 cells.^{6,7} The emerging regulatory T cell/T_H1-like cytokine profile presumably induces B cells to undergo isotype switching. After discontinuation of immunotherapy, as allergen-specific IgG₄ levels eventually return to near-baseline levels, allergen-specific IgE levels gradually recover. In spite of this, the clinical benefits of ASIT prevail as long as 2 years after discontinuation of treatment. This seemingly paradoxical finding was only recently explained by the persistence of a few highly bioactive IgG antibodies that competitively inhibit the binding of IgE-allergen complexes to the surface of immune effector cells.⁸ How this selective persistence of inhibitory antibodies is achieved is not known.

With respect to predictors of successful immunotherapy, a high ratio of serum specific to serum total IgE was found to correlate with the effectiveness of ASIT.⁹ However, given the fact that specific IgE levels to seasonal allergens, such as pollen, can vary considerably depending on seasonal changes in exposure, it remains to be determined how solid this relationship is in predicting the outcome of ASIT. Conclusively, many questions remain in explaining how and why immunotherapy does or does not work. To address these questions, we have to better understand the early immunologic steps that ultimately result in a protective antibody response. In fact, a key might be to learn more about the T-cell responses to allergens in healthy subjects, allergic patients, and patients undergoing immunotherapy.

When attempting to analyze allergen-specific T-cell responses *ex vivo*, one inevitably encounters the problem of low precursor frequencies. The seminal work by Wambre et al² deals with this problem in an elegant way by using allergen peptide-specific MHC class II tetramers. The tetramer technique, formerly restricted to MHC class I-restricted peptides, now allows *ex vivo* monitoring of allergen-specific T_H cells without the requirement of prolonged *in vitro* expansion.¹⁰ The present work of Wambre et al² focuses on the comparison of allergen-specific CD4⁺ T cells of alder pollen-tolerant subjects, patients with alder pollen allergy, and patients with alder pollen allergy who successfully completed ASIT. The authors show that CD4⁺ T cells specific for the major allergen Aln g 1 are present in both tolerant and allergic subjects reacting to the same immunodominant epitope; however, they are present at different frequencies. These cells predominantly display a memory phenotype and are functionally active during natural pollen exposure in nonallergic and allergic subjects. The key finding is that Aln g 1-specific CD4⁺ T cells from alder pollen-tolerant subjects and patients with alder pollen allergy differ in their differentiation state: Aln g 1-specific CD4⁺ T cells from alder pollen-tolerant subjects express CD27,

From ^athe Center of Allergy and Environment (ZAUM), Technische Universität and Helmholtz Center, Munich, and ^bthe Department of Dermatology, Technische Universität Munich.

Supported in part by the CK-Care (Christine Kühne) Center for Allergy Research and Education and DFG grant TR467/5-1.

Disclosure of potential conflict of interest: The authors declare that they have no relevant conflicts of interest.

Received for publication October 31, 2011; revised November 28, 2011; accepted for publication December 12, 2011.

Corresponding author: Claudia Traidl-Hoffmann, MD, Center of Allergy and Environment (ZAUM), Technische Universität and Helmholtz Zentrum München, Biedersteinerstr 29, 80802 München, Germany. E-mail: traidl-hoffmann@lrz.tum.de.

J Allergy Clin Immunol 2012;129:552-4.
0091-6749/\$36.00

© 2012 American Academy of Allergy, Asthma & Immunology
doi:10.1016/j.jaci.2011.12.967




FIG 1. Changes in T-cell and antigen responses during ASIT. In susceptible subjects naturally exposed to an allergen, dendritic cell (DC)-derived signals lead to the differentiation of Th2 cells, which induce specific IgE production in B cells. During ASIT, increasing doses of allergen are administered. Through mechanisms that are incompletely understood to date, this licenses DCs to induce the differentiation of regulatory T (Treg) cells, which functionally inhibit the allergen-specific effector cells and promote the production of specific inhibiting IgG₄ antibodies by B cells. Wambre et al² now provide evidence that in patients who successfully completed ASIT, allergen-specific effector (Th2) cells are selectively deleted while allergen-specific Th1-like cells prevail. Modified with permission from Akdis and Akdis.³

which is concordant with a central memory phenotype. In contrast, Aln g 1-specific CD4⁺ T cells from patients with alder pollen allergy fall into 2 subsets, with the smaller subset expressing and the larger subset lacking CD27, marking them as terminally differentiated effector cells. Cytokine and chemokine profiles of the 2 subsets are highly divergent: the CD27⁺ subset expresses CCR7 and Th1-associated markers, such as CXCR3 and IFN-γ, whereas the CD27⁻ cells are CCR7⁻CCR4⁺Th2⁺ and express the Th2 cytokines IL-4, IL-5, and IL-13. Most interestingly, this CD27⁻ population of Aln g 1-specific Th2 cells was preferentially deleted in patients after successfully completed immunotherapy, whereas their Th1-like CD27⁺ counterparts prevailed.

The finding that allergen-specific Th2 cells are highly differentiated effector cells characterized by loss of CD27 expression is in good agreement with recent data on the heterogeneity of Th2 cells either analyzed *ex vivo* or differentiated by *in vitro* differentiation protocols. This work showed that IL-4⁺IL-13⁺ Th2 cells coexpressing IL-5 are CD27⁻ are generated after recurrent antigenic exposure and represent a subset of highly differentiated T cells.¹¹ Interaction of the costimulatory molecule CD27 on the T cell with its ligand, CD70, on dendritic cells has recently been implicated in supporting the differentiation of Th1 cells.^{12,13} On the T-cell side, CD70 expression is restricted to Th1 cells and might serve to amplify Th1-instructing signals in T/T-cell interactions through a positive feedback mechanism.¹² This raises the question of whether loss of CD27 expression on allergen-specific CD4⁺ T cells is *per se* sufficient and necessary for the progression of differentiation into pathogenic Th2 cells. It would certainly be interesting to compare CD27 expression on allergen-specific memory T cells

of nonsensitized subjects, subjects who are sensitized but asymptomatic, and sensitized subjects with clinical allergic symptoms.

Another important issue to be addressed in future studies is to examine the role of CD27⁻ allergen-specific CD4⁺ T cells in patients who have completed specific immunotherapy but are clinically nonresponsive. It is to be expected that a deletion of the CD27⁻ allergen-specific CD4⁺ T-cell subset will not be observed in these patients. Future prospective studies that monitor CD27 expression on allergen-specific T cells during the course of ASIT will reveal whether CD27 is a suitable early marker distinguishing between responders and nonresponders of immunotherapy.

The findings of Wambre et al,² originally linked to the allergy immunotherapy field, might even reflect a general principle in immune responses to vaccination. Of note, a recent report assessed the T-cell response to different vaccinia virus strains. Here a strongly replicating vaccinia virus strain that promoted the generation of high numbers of protective memory CD8⁺ T cells engaged the TNF receptor family costimulatory receptors OX40 and CD27, whereas a weakly replicating strain, which was a poor inducer of a protective CD8⁺ T cell response, did not engage OX40 or CD27.¹⁴ Engagement of CD27 might therefore turn out not only to be a surrogate for successful immunotherapy but also a novel tool to enhance the power of allergen vaccines.

REFERENCES

1. Ring J, Guterthum J. 100 years of hyposensitization: history of allergen-specific immunotherapy (ASIT). *Allergy* 2011;66:713-24.
2. Wambre E, Delong JH, James EA, Lafond RE, Robinson D, Kwok WW. Differentiation stage determines pathologic and protective allergen-specific CD4⁺ T-cell outcomes during specific immunotherapy. *J Allergy Clin Immunol* 2012;129: 544-51.e7.

3. Akdis CA, Akdis M. Mechanisms of allergen-specific immunotherapy. *J Allergy Clin Immunol* 2011;127:18-29.
4. Satoguina JS, Adjibimey T, Arndts K, Hoch J, Oldenburg J, Layland LE, et al. Tr1 and naturally occurring regulatory T cells induce IgG4 in B cells through GITR/GITR-L interaction, IL-10 and TGF-beta. *Eur J Immunol* 2008;38:3101-13.
5. Francis JN, James LK, Paraskevopoulos G, Wong C, Calderon MA, Durham SR, et al. Grass pollen immunotherapy: IL-10 induction and suppression of late responses precedes IgG4 inhibitory antibody activity. *J Allergy Clin Immunol* 2008;121:1120-5, e2.
6. Van Overtvelt L, Wambre E, Maillere B, von Hofe E, Louise A, Balazuc AM, et al. Assessment of Bet v 1-specific CD4+ T cell responses in allergic and nonallergic individuals using MHC class II peptide tetramers. *J Immunol* 2008;180:4514-22.
7. Wambre E, Bonvalet M, Bodo VB, Maillere B, Leclert G, Moussu H, et al. Distinct characteristics of seasonal (Bet v 1) vs. perennial (Der p 1/Der p 2) allergen-specific CD4(+) T cell responses. *Clin Exp Allergy* 2011;41:192-203.
8. James LK, Shamji MH, Walker SM, Wilson DR, Wachholz PA, Francis JN, et al. Long-term tolerance after allergen immunotherapy is accompanied by selective persistence of blocking antibodies. *J Allergy Clin Immunol* 2011;127:509-16, e1-5.
9. Di Lorenzo G, Mansueto P, Pacor ML, Rizzo M, Castello F, Martinelli N, et al. Evaluation of serum s-IgE/total IgE ratio in predicting clinical response to allergen-specific immunotherapy. *J Allergy Clin Immunol* 2009;123:1103-10, e1-4.
10. Kwok WW, Roti M, Delong JH, Tan V, Wambre E, James EA, et al. Direct ex vivo analysis of allergen-specific CD4+ T cells. *J Allergy Clin Immunol* 2010;125:1407-9, e1.
11. Upadhyaya B, Yin Y, Hill BJ, Douek DC, Prussin C. Hierarchical IL-5 expression defines a subpopulation of highly differentiated human Th2 cells. *J Immunol* 2011;187:3111-20.
12. Kawamura T, Ogawa Y, Shimozato O, Ando T, Nakao A, Kobata T, et al. CD70 is selectively expressed on Th1 but not on Th2 cells and is required for Th1-type immune responses. *J Invest Dermatol* 2011;131:1252-61.
13. Libregts S, van Olfen RW, van der Sluijs KF, van Lier RA, Nolte MA. Function of CD27 in helper T cell differentiation. *Immunol Lett* 2011;136:177-86.
14. Salek-Ardakani S, Choi YS, Rafii-El-Idrissi Benhnia M, Flynn R, Arens R, Shoenberger S, et al. B cell-specific expression of B7-2 is required for follicular Th cell function in response to vaccinia virus. *J Immunol* 2011;186:5294-303.